Impact of myelodysplasia-related gene mutations and residual mutations at remission in venetoclax/azacitidine for AML

Leukemia

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

Leuk Lymphoma

Huang YH, Liu FT, Wan CL, Wang ZJ, Liu YQ, Cao HY, Huang SM, Tan KW, Ge SS, Wang M, Liu MJ, Wang ZH, Lyu XY, Dai HP, Li Z, Xue SL

doi: 10.1080/10428194.2025.2566317

Leukemia

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Leukemia

Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V

doi: 10.1038/s41375-025-02730-3

Leukemia

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Am J Hematol

Esteve J, Nagler A, Labopin M, Versluis J, Sanz J, Gedde-Dahl T, Burns D, Roeven M, Labussière-Wallet H, Borne PVD, Van Gorkom G, Contentin N, Neubauer A, Wagner-Drouet EM, Kröger N, Mohty M, Ciceri F

doi: 10.1002/ajh.27647

Leukemia

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica

Short NJ, Loghavi S, Yilmaz M, Karrar O, Kim K, Dinardo CD, Kadia TM, Maroun M, Borthakur G, Issa GC, Jabbour J, Oran B, Shpall EJ, Popat U, Patel KP, Routbort M, Konopleva M, Ravandi F, Kantarjian H, Daver N

doi: 10.3324/haematol.2025.288553

Leukemia

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML

Blood

Lu J, Xue S, Wang Y, He X, Hu X, Miao M, Zhang Y, Tang Z, Xie J, Yang X, Xu M, Shen Y, Du F, Wu Q, Xue M, Wang Y, Deng A, Dou X, Xu Y, Dai H, Wu D, Chen S

doi: 10.1182/blood.2024027217

Leukemia

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Blood

Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink A, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer AP, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindstrom V, Staber PB, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann CU, Fischer K, Eichhorst BF, Hallek MJ

doi: 10.1182/blood.2025028899

Leukemia

Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study

Br J Haematol

Ye Y, Liu X, Dai H, Hu J, Yu G, Zhang Y, Weng G, Lin D, Du X, Xiao J, Sun Z, Zhang H, Liang X, Guo Z, Xu N, Fan Z, Xuan L, Lin R, Yin Z, Huang F, Dai M, Li Z, Liu Q, Jin H

doi: 10.1111/bjh.20147

Lung, Respiratory and Thoracic Cancer

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project

Eur J Cancer

Molina-Vila MA, Tsourti Z, Vervita K, Bertran-Alamillo J, García-Peláez B, Kerr KM, Bubendorf L, Madsen LB, Biernat W, Stenzinger A, Haberecker M, Blackhall F, Pokharel S, Jordana-Ariza N, Vives-Usano M, Vagenknecht P, Dafni U, Kammler R, Finn SP, Peters S, Stahel RA, Rosell R

doi: 10.1016/j.ejca.2026.116583

Leukemia

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study

Am J Hematol

Aspas Requena G, Montesinos P, Bérard E, Bertoli S, Rodríguez-Veiga R, Simand C, Torres L, Peterlin P, Tormo M, Birsen R, Bergua-Burgues JM, Tavernier E, Bernal Del Castillo T, Carré M, Gil C, Contejean A, Rodríguez-Arbolí E, Orvain C, Rodríguez-Medina C, Veronese L, Sayas Lloris MJ, Delabesse E, Serrano J, Mineur A, García-Fortes M, Guieze R, Amigo ML, Pigneux A, Algarra Algarra L, Recher C, Dumas PY, Martínez-Cuadrón D

doi: 10.1002/ajh.70233

Related content

Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL

Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study

Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study